BMY stock news · Bristol Myers Squibb
Get alerts for BMY
Follow Bristol Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BMYMorgan Stanley says Bristol Myers Squibb is still a weak choice and has cut its price target to $40.
Bad for BMYMorgan Stanley kept its view that Bristol Myers Squibb shares may lag and cut its target price, a negative signal for the shares.
Goldman Sachs has cut its price target for Bristol-Myers Squibb from $63 to $61.
Bad for BMYGoldman cut its price target on Bristol-Myers Squibb from $63 to $61. That is a modest negative signal, with no new company results reported.
Bristol Myers Squibb shares early results for its CAR T-cell treatment for multiple sclerosis.
NeutralBristol Myers Squibb reported possible benefits for an early multiple sclerosis treatment study, alongside side effects and a separate fatal pneumonia report. The findings leave the treatment's promise unsettled.
Tempus AI, Inc.: Other Events (TEM)
NeutralBristol Myers gets access to more cancer and brain data for drug development, but pays for that access. The filing reports no resulting change in products or sales, so it does not change the company's outlook.
Goldman Sachs says to keep holding Bristol Myers Squibb shares, aiming for a price of $63 each.
NeutralGoldman Sachs kept its Hold rating and $63 target for Bristol Myers Squibb. With no new company results or drug news, the report does not change its outlook.
Bristol Myers Squibb's stock is up on Monday after good news about its drug trials.
Good for BMYBristol Myers Squibb reported success in 2 late-stage drug trials, though one dose did not show a clear result. The findings support its future treatments.
Today, big investors are making moves with 10 health care stocks.
NeutralBristol-Myers Squibb appeared in a report of bullish put trading. The report gives no company news, so it does not change the outlook for BMY.
Bristol Myers Squibb's Zenbexus helps blood cancer patients, lowering the chance of disease worsening by 51%.
Good for BMYBristol-Myers Squibb reported that Zenbexus cut the risk of cancer progression or death. The trial results support the drug’s use in multiple myeloma.
Following the identification of a trial halt by a Wall Street analyst, reports emerged regarding three fatalities.
Bad for BMYBristol Myers Squibb and Novartis have both delayed clinical trials for their CAR-T therapies due to serious safety concerns, including patient deaths and adverse events, which were not disclosed to the public in a timely manner.
Bristol Myers Squibb secures FDA approval for innovative multiple myeloma therapy.
NeutralBristol Myers Squibb received FDA accelerated approval for Zenbexus, a novel treatment for multiple myeloma, which is expected to significantly enhance its market position and revenue potential in the oncology sector. This approval is based on promising trial results, marking a pivotal moment for the company.
After facing two setbacks and a complicated journey, Replimune has successfully obtained FDA approval for its skin cancer therapy.
Good for BMYPartnership with Replimune for the combination treatment with Opdivo enhances its product offering in oncology.